Form 6-K ASTRAZENECA PLC For: Dec 05
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of��December 2014
Commission File Number:��001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X �����������Form 40-F��__
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): �����������
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes��__�����������������No X
If Yes is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):���82-_____________
�
�
�
JURY VERDICT FAVOURS ASTRAZENECA IN
NEXIUM ANTITRUST LITIGATION
AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.
AstraZeneca is pleased with the jury's verdict. The Company has always maintained that the plaintiffs' allegations were without merit.
All parties have appellate rights.
Two cases making similar allegations were filed by numerous purchasers in the state court in Pennsylvania and are still pending.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Esra Erkal-Paler�������������������������������������������+44 20 7604 8030 (UK/Global)
Vanessa Rhodes�����������������������������������������+44 20 7604 8037 (UK/Global)
Ayesha Bharmal�����������������������������������������+44 20 7604 8034 (UK/Global)
Jacob Lund��������������������������������������������������+46 8 553 260 20 (Sweden)
Michele Meixell�������������������������������������������+ 1 302 885 6351 (US)
Investor Enquiries
Thomas Kudsk Larsen�������������������������������+44 20 7604 8199����������������mob: +44 7818 524185
Karl H�rd����������������������������������������������������� +44 20 7604 8123������������mob: +44 7789 654364
Eugenia Litz�������������������������������������������������+44 20 7604 8233����������������mob: +44 7884 735627
Christer Gruvris�������������������������������������������+44 20 7604 8126����������������mob: +44 7827 836825
5 December 2014
-ENDS-
�
�
�
�
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
Date:�05 December�2014
|
By:��/s/ Adrian Kemp
|
� |
Name: Adrian Kemp
|
� |
Title: Company Secretary
|
�
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- ROSEN, NATIONAL TRIAL LAWYERS, Encourages Northern Genesis Acquisition Corp. n/k/a The Lion Electric Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – NGA
- Banco Itaú Chile Files Material Event Notice announcing Extraordinary General Shareholders’ Meeting Agreements
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!